Provides an update on the appropriate use of non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients.
Answers are grounded in this paper and cite their sources.
Supports refined imaging selection in hypertension; leaves open need for prospective outcome validation.
Arterial hypertension (HTN) accounts for the largest amount of attributable cardiovascular (CV) mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by HTN represents an independent determinant of CV risk and the identification of target organ damage (TOD) is recommended to further reclassify patients' risk. Non-invasive CV imaging is progressively being used and continues to provide new technological opportunities to TOD evaluation at early stage. The aim of this article is to provide the community of cardiology with an update on appropriate and justified use of non-invasive imaging tests in the growing population of hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Filardi et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: